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Proteoglycans (PGs) are implicated in the growth and progression of malignant tumors. In this study, we examined the concentration and
localization of PGs in advanced (stage IV) laryngeal squamous cell carcinoma (LSCC) and compared with human normal larynx (HNL).
LSCC and HNL sections were examined immunohistochemically with a panel of antibodies, and tissues extracts were analyzed by
biochemical methods including immunoblotting and high performance liquid chromatography (HPLC). The results demonstrated significant
destruction of cartilage in LSCC, which was followed by marked decrease of aggrecan and link protein. In contrast to the loss of aggrecan in
LSCC, accumulation of versican and decorin was observed in the tumor-associated stroma. Biochemical analyses indicated that aggrecan,
versican, decorin and biglycan comprise the vast majority of total PGs in both healthy and cancerous tissue. In LSCC the absolute amounts of
KS/CS/DS-containing PGs were dramatically decreased about 18-fold in comparison to HNL. This decrease is due to the loss of aggrecan.
Disaccharide analysis of CS/DSPGs from LSCC showed a significant reduction of 6-sulfated D-disaccharides (Ddi-6S) with a parallel
increase of 4-sulfated D-disaccharides (Ddi-4S) as compared to HNL. The obtained data clearly demonstrate that tumor progression is closely
related to specific alteration of matrix PGs in LSCC. The altered composition of PGs in cartilage, as well as in tumor-associated stroma, is
crucial for the biological behaviour of cancer cells in the diseased tissue.
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1. Introduction which many chondroitin sulfate (CS) and keratan sulfateLarynx is a uniquely complicated organ that is strategi-
cally located so that significant alteration of its anatomy can
have a noticeable impact on vocal, respiratory, and swallow-
ing physiology. The laryngeal cartilage, which is represented
from four kinds of cartilage (cricoid, epiglottis, paired
arytenoids, and shield-like thyroid cartilage), comprises the
skeletal structure of the larynx [1]. The major extracellular
matrix (ECM) components of cartilage are collagen type II
and the large aggregating proteoglycan (PG), aggrecan.
Aggrecan is consisted by an extended protein core onto0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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(N. Papageorgakopoulou).(KS) side chains are covalently bound. Cartilage contains
also the two types of small size CS or/and dermatan sulfate
(DS)-containing PGs, decorin and biglycan, which, in con-
trast to the large size aggrecan, carry only one or two side
chains, respectively; the type of side chains varying with the
tissue of origin. The small-sized PGs represent only 1–2%
of the total mass of PGs in the cartilage [2–4].
Maintenance of the PG composition and content of
cartilage is critical for the structural integrity and function
of the tissue. One of the central pathophysiological
features contributing to cartilage erosion during degener-
ative joint disease is the increased catabolism and loss of
the large aggregating cartilage PG, aggrecan [5,6]. Deg-
radation of cartilage involves proteolytic cleavage of both
its major structural elements, namely aggrecan and type II
collagen. Proteolysis and subsequent loss of the GAG rich
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cartilage degeneration, while significant catabolism of the
collagen fibrillar structure occurs later and may represent
the point of irreversible cartilage damage [7].
Substantial experimental and clinical evidences suggest
that the catabolism of ECM components is a prerequisite for
invasive and metastatic behavior of solid tumors [8].
In a previous study [9], glycosaminoglycans (GAGs)
from cancerous human laryngeal cartilage and normal
adjacent tissue were isolated and characterized by means
of enzyme susceptibility and high performance liquid
chromatography (HPLC). It was shown that normal adja-
cent laryngeal tissue contains all known GAG species, the
content and composition of which were altered in laryngeal
carcinoma. It is known that in advanced LSCC (stages III
and IV) many of these lesions are associated with cartilage
destruction and the tumor invades through it and/or extents
into soft tissues of the neck [1,10]. This issue is an
important one because destruction of the PG-rich ECM
of cartilage in laryngeal cancer is likely to be a prerequisite
for invasive and metastatic behaviour.
There is a lack of information on the metabolism of
PGs in human laryngeal carcinoma. The aim of this study
was to evaluate the state of matrix PGs in cartilage as well
as in the tumor stroma in advanced LSCC. The results of
this study, which is the first detailed study on this field,
indicated significant compositional and structural altera-
tions in PG components examined. The significant find-
ings of this study were the dramatic loss of aggregate
components, i.e. aggrecan and link protein, the altered
sulfation pattern of the galactosaminoglycan (CS/DS)
chains and the increased levels of peritumoral versican
and decorin in LSCC.2. Materials and methods
2.1. Chemicals
Monoclonal antibodies 6B6 (against the protein core of
decorin), 2B1 (against the protein core of versican) and 5D4
(against KS) were purchased from Seikagaku (Japan).
Monoclonal antibodies 3B3 (against chondroitin/dermatan-
6-sulfate stubs), 2B6 (against chondroitin/dermatan-4-sul-
fate stubs), 9/30/8A4 (against an epitope located at the C-
terminal part of link protein), PR 8A4 (against biglycan) and
1C6 against the hyaluronan binding region of aggrecan were
generous gifts of Prof. B. Caterson (University of Cardiff,
UK). Polyclonal antibodies raised in rabbits against aggre-
can and link protein were prepared in our laboratories. Goat
anti-rabbit and anti-mouse IgG, both conjugated with per-
oxidase, guanidine HCl (GdnHCl) grade I, cesium chloride
(CsCl), benzamidine–HCl, phenylmethylsulfonyl fluoride
(PMSF), N-ethylmaleimide (NEM), 6-aminohexanoic acid,
cetylpyridinium chloride (CPC), were from Sigma Chemical
Co. (St. Louis. MO, USA). Moreover, 2 crystallizedpapain (EC 3.4.22.2), chondroitinase ABC from Proteus
vulgaris (EC 4.2.2.4), chondroitinase AC II from Arthro-
bacter aurescens (EC 4.2.2.5), keratanase from Pseudomo-
nas sp. (EC 3.2.1.103) and DEAE-Sephacel were from
Sigma. All other chemicals used were of the best grade
commercially available.
2.2. Analytical methods
The sulfated GAG (SGAG) content of isolated total PGs
and purified galactosaminoglycan-containing PGs (Gal-
AGPGs) was estimated by using the metachromatic dye
1,9-dimethyl methylene blue [11]. Total PGs and Gal-
AGPGs content, expressed as CS equivalents per wet
weight of tissue, were derived (without correction for KS
or other components contributing to the change in absor-
bance) from a calibration curve created using whale CS as a
standard. The amounts and types of the unsaturated dis-
accharides released by chondroitinase ABC or AC II were
determined by HPLC [12].
2.3. Tissue source
Specimens of human normal larynx (HNL) (n = 4,
25–55 years old) were obtained from autopsies and
frozen at  20 jC. The cancerous specimens were
obtained from the larynx after total laryngectomy for
laryngeal carcinoma. The specimens obtained from each
patient were transferred to the laboratory, separated from
surrounding tissues and used in the subsequent experi-
ments. Eight patients with advanced laryngeal squamous
cell carcinoma (LSCC) were included in the study. The
specimens, containing cartilage and soft tissue, were
classified according to UICC classification system and
were characterized as advanced LSCC, stage IV. The
Ethical Committee of the University Hospital of Patras
approved the study design and informed consent was
obtained from all patients before entry into the study.
For biochemical analyses of the cancerous and normal
laryngeal tissues, we separated cartilaginous and non-
cartilaginous parts of the samples and we obtained
aliquots of the tissues containing almost equal percen-
tages of cartilaginous and non-cartilaginous tissues.
2.4. Extraction of PGs
For PG analysis, tissue aliquots (200–600 mg of wet
weight of tissue) were extracted by gentle shaking for 24 h at
4 jC with 10 vol. of 4 M guanidinium HCl (GdnHCl). The
GdnHCl solutions were buffered with 0.05 M sodium
acetate pH 5.8 [13]. The extracting solution contained
0.01 M disodium EDTA, 0.005 M benzamidine–HCl, 0.1
M 6-aminohexanoic acid and 0.004 M PMSF as protease
inhibitors [14]. NEM (0.01 M) was also included to avoid
disulfide exchange [15]. The extraction mixture was filtered
and the filtrate was retained. The residues were re-extracted
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extracting solution. The two extracts were then pooled and
aliquots from each combined extract were used for various
chemical analyses. Known amounts of residual tissues after
double extraction were washed with water and then digested
with papain and analysed for their chemical composition.
The extracts were collected and stored at  20 jC for
further experiments and analyses.
2.5. Isolation and purification of PGs
In order to isolate total PGs from each specimen, equal
parts from each specimen extract were subjected to precip-
itation with 5 vol. of ethanol. The isolated PGs were
dissolved in 10 M formamide–0.05 M sodium acetate, pH
6.0, containing 0.2% (v/v) Triton X-100 and the proteinase
inhibitors and were applied on to a DEAE-Sephacel column,
which was equilibrated with the same buffer [16]. HA was
eluted by washing of the column with 3 vol. of the same
buffer containing 0.3 M NaCl. PGs were fractionated by
elution of the column with 10 vol. of a linear gradient
ranging from 0.3 M–0.85 M NaCl in formamide buffer
[17]. Fractions obtained with 0.4–0.5 M NaCl and 0.55–0.7
M NaCl corresponded to heparan sulfate PGs (HSPGs) and
GalAGPGs, respectively, confirmed by chemical and elec-
trophoretic analyses as described before [17]. GalAGPG
fractions were pooled and concentrated for further experi-Fig. 1. Localization of aggrecan (A and C) and link protein (B and D) in HNL (A a
antibody against aggrecan or 1C6 monoclonal antibody. Link protein was immunol
(A–D). The destruction and ossification of the cartilage is showed by the symbo
cancer cells in the vicinity of the ossified cartilage (original magnification  250ments. HSPG fractions were not further examined in this
study.
2.6. Enzymatic degradations
Digestions with papain were performed at 60 jC for
18 h (0.2 mg of papain/g wet weight of tissue) in 0.1 M
Tris–HCl, pH 7.2, containing 0.01 M disodium EDTA
and 0.005 M cysteine–HCl. For chondroitinase ABC or
chondroitinase AC II digestions, solutions of GAGs or
PGs (1 mg of uronic acid/ml) in 0.1 M Tris–acetate, pH
7.3, were incubated at 37 jC for 4 h in the presence of
0.1 unit of chondroitinase ABC or AC II per milliliter.
For keratanase digestion, the samples were incubated at
37 jC for 4 h in 0.1 M Tris–HCl, pH 7.4, in the
presence of 0.1 unit of keratanase per micromole of
galactose. Heating the solutions at 100 jC for 3 min
terminated the digestions.
2.7. SDS/PAGE and western blotting
Polyacrylamide gel electrophoresis (PAGE) was per-
formed on gels of linear gradient concentration of
acrylamide (4 – 20%) according to the method of
Laemmli [18]. Samples of isolated PGs, as well as tissue
extracts derived from equal wet weight of tissues, were
treated with chondroitinase ABC and/or keratanases andnd B) and LSCC (C and D). Sections were stained using either a polyclonal
ocalized using 9/30/8A4 monoclonal antibody. Original magnification  50
l z in the corresponding specimens of LSCC. Insets indicate the mass of
). (For color see online version).
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lidene difluoride (PVDF) membranes (Immobilon-P) at a
constant current of 80 mA at 4 jC for 20 h in 0.05 M
Tris–HCl, pH 8.3. The membranes were washed with
0.14 M NaCl in 0.01 M phosphate buffer, pH 7.2,
containing 0.1% (v/v) Tween-20 (PBS-T) and blocked
with 5% dry defatted milk (DDM) in PBS-T. They were
then immersed in antibody solution against either versi-
can (2B1), decorin (6B6), link protein (9/30/8A4), bigly-
can (PR 8A4), KS (5D4), chondroitin/dermatan-6-sulfate
stubs (3B3), chondroitin/dermatan-4-sulfate stubs (2B6),
diluted 1:2000 or aggrecan diluted 1:5000 in PBS-T–1%
DDM and incubated for 1 h at room temperature. After
repeated washings with PBS-T, the membranes were
immersed in the appropriate second antibody diluted
1:5000 in PBS-T–1% DDM, incubated for 1 h at roomFig. 2. Localization of 6-sulfated stubs (A and D), 4-sulfated stubs (B and E) and
stained using 3B3, 2B6 and 5D4 monoclonal antibodies against 6-sulfated, 4-sulfat
(D–F). (For color see online version).temperature and washed exhaustively with PBS-T. The
immunoreacting bands were visualized by using the ECL
reagents (Amersham, UK) according to the manufactur-
er’s instructions and by exposure to Agfa Curix X-ray
film. Exposure varied from 1 to 30 min, depending on
the experiment.
2.8. Immunohistochemistry
Specimens processed for light microscopy were fixed
in 4% (v/v) buffered formaldehyde for 40 h at 4 jC,
embedded in paraffin and sections of 5 Am were taken.
Following dewaxing and rehydration, the sections were
treated with 1 unit/ml chondroitinase ABC for 15 min at
37 jC to detach GAG chains from the protein core.
Endogenous peroxidase activity was quenched with 3%KS (C and F) in HNL (A, B and C) and LSCC (D, E and F). Sections were
ed stubs and KS, respectively. Original magnification  25 (A–C) and  50
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Nonspecific antibody binding was blocked by incubation
with 3% (v/v) normal rabbit or swine serum in PBS for
20 min at room temperature. The slides were incubated
with primary antibodies (polyclonal anti-aggrecan, 1:500;
1C6, 1:500; 9/30/8A4, 1:500; 5D4, 1:4000; 6B6, 1:1000;
2B1, 1:1000; 2B6, 1:2000; 3B3, 1:333) diluted in PBS
containing 1% (v/v) normal rabbit or swine serum over-
night at 4 jC. The slides stained with 1C6 and 9/30/8A4
were reduced and alkylated following incubation with 10
mM dithiothreitol in 50 mM Tris–HCl–200 mM NaCl,
pH 7.4, for 2 h at 37 jC and 40 mM iodoacetamide in
PBS for 1 h at 37 jC, respectively, before the treatment
with chondroitinase ABC. The obtained antigen–antibody
complexes were visualized by 30-min incubation at room
temperature using biotinylated rabbit anti-mouse antibody
or biotinylated goat anti-rabbit antibody diluted 1:200 and
the avidin-biotin peroxidase technique (Dakopatts) accord-
ing to manufacturer’s instructions. The staining was
developed with 3,3-diaminobenzidine (DAB)/hydrogen
peroxide for 5 min at room temperature and slides were
counterstained with hematoxylin.Fig. 3. Versican (A and C) and decorin (B and D) immunolocalization in HNL (A
antibodies, respectively. Original magnification  25 (A and B) and  50 (C an
formed matrix in the destructed and ossified cartilage in the corresponding specime
cancerous tissue surrounding the destructed and ossified cartilage (original magn2.9. Statistical analysis
Statistically significant differences were evaluated by t-
test using the microcall origin software (version 3.2).
hysica Acta 1689 (2004) 152–1613. Results
3.1. Immunohistochemical studies
We examined the distribution of PGs, GAG chains,
disaccharide stubs of GAG chains and link protein in HNL
and LSCC. Both normal and neoplastic epithelia were neg-
ative for the presence of aggrecan and link protein (figure not
shown) indicating that epithelial and fibroblast cells do not
express aggrecan and link protein (aggregate components). In
contrast, the loose connective tissue surrounding cartilage
and cartilage of HNL and LSCC showed various degrees of
immunoreactivity with all the antibodies tested. Strikingly,
the immunostaining of the aggregate components in HNL
(Fig. 1A and B, respectively) was different from that in LSCC
(Fig. 1C and D, respectively), displaying significantly de-and B) and LSCC (C and D) was examined using 2B1 and 6B6 monoclonal
d D). Asterisks indicate the staining of versican and decorin in the newly
ns. Insets show the intratumorous localization of versican and decorin in the
ification  250). (For color see online version).
Fig. 4. (A) Quantification of total and KS/CS/DS-containing PGs in LSCC
and HNL. The amounts of PGs are expressed as milligrams of sulfated
GAGs per gram of wet weight of tissue. (B) Percentage composition of
disaccharides present on CS/DS-PGs in LSCC and HNL. Values are the
meanF S.D. *PV 0.05.
Fig. 5. Immunoblot analyses of HNL and LSCC for aggrecan (A), link
protein (B) and versican (C). Isolated PGs were treated with chondroitinase
ABC and keratanases, electrophoresed on 4–20% SDS-PAGE and blotted
on membranes. The membranes were probed with polyclonal antibody
against aggrecan and 2B1 monoclonal antibody against versican. Tissues
extracts were also analysed for the presence of link protein using 9/30/8A4
monoclonal antibody. Figure indicates a representative case.
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rous cartilage of LSCC when compared with those from
normal cartilage in HNL. A similar distribution pattern with
that of aggrecan in both HNL and LSCC was also observed
for the chondroitin/dermatan 6-sulfate (Fig. 2A and D,
respectively), chondroitin/dermatan 4-sulfate epitopes (Fig.
2B and E, respectively) and KS (Fig. 2C and F, respectively),
since these epitopes and KS are intrinsic components of the
aggrecan molecules.
These CS/DS stubs and KS showed a marked reduction
in the peritumorous cartilage of LSCC in comparison to
HNL following the decrease of aggrecan in the diseased
tissue. As shown by the distribution of the major compo-
nents of the cartilage, the advanced LSCC is associated to
marked destruction of cartilage (Figs. 1 and 2). The latter is
often accompanied by ossification and invasion by inflam-
matory and/or cancer cells (Figs. 1 and 2).
The use of 2B1 and 6B6 monoclonal antibodies, which
recognize versican and decorin, respectively, showed a dif-
ferent distribution of these PGs between normal and neoplas-
tic tissues. Decorin and versican are located in the loose
connective tissue between epithelial cells and cartilage in
HNL. Decorin exhibited a more intense reactivity in com-
parison to versican and was far more prominent in perichon-
drium (Fig. 3A and B). In LSCC, prominent immunostaining
for versican and decorin was observed in stroma (Fig. 3C and
D) associated with malignant areas of sectioned laryngeal
tissue, whereas lower amounts of versican and decorin wereidentified in stroma surrounding nonmalignant tissues. Fur-
thermore, a strong immunostaining for versican but not for
decorin was found in the newly formed matrix of the
remodeled- ossified cartilage in LSCC.
3.2. PG analysis
The concentration of total isolated and purified by anion-
exchange chromatography PGs from each normal and
cancerous specimen was estimated based on the content of
SGAGs. The elution profiles from DEAE-Sephacel column
Fig. 6. Immunoblot analyses of HNL and LSCC for biglycan (A) and
decorin (B). Isolated PGs were treated with chondroitinase ABC and
keratanases, electrophoresed on 4–20% SDS-PAGE and blotted on
membranes. The membranes were probed with PR 8A4 and 6B6
monoclonal antibodies against biglycan and decorin, respectively. Tissues
extracts were also analysed for the presence of non-glycanated forms of
decorin. Figure indicates a representative case.
Fig. 7. Immunoblot analyses of HNL and LSCC for 6-sulfated stubs (A), 4-
sulfated stubs (B) and KS (C). Isolated PGs were treated with
chondroitinase ABC and keratanases (A and B), or only with chondroi-
tinase ABC (C), electrophoresed on 4–20% SDS-PAGE and blotted on
membranes. The membranes were probed with 3B3, 2B6 and 5D4
monoclonal antibodies against 6-sulfated, 4-sulfated stubs and KS,
respectively. Figure indicates a representative case.
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PGs was KS/CS/DS-containing PGs and was eluted with
0.55–0.7 M NaCl. The quantitative data (Fig. 4A) showed a
dramatic decrease of the absolute amounts of both total PGs
and KS/CS/DS-PGs in LSCC, about 9-fold and 18-fold,
respectively, in comparison to HNL.
Isolated PGs from each normal and cancerous specimen
were exhaustively digested with chondroitinase ABC, which
totally degrades the galactosaminoglycan (CS/DS) chains.
HPLC analysis of the CS/DS-derived D-disaccharides indi-
cated that Ddi-6S and Ddi-4S disaccharides represent 52%
and 48%, respectively, of chondroitinase ABC derived
disaccharides in samples from HNL (Fig. 4B). The propor-
tion of Ddi-6S was significantly decreased from 52% to
27% in LSCC, indicating that Ddi-4S disaccharides predo-
minated in LSCC. Traces of non-sulfated D-disaccharides
were detected in the PG digests with chondroitinase ABC
from both normal and cancerous specimens.
3.3. Western blot analyses
Aliquots of PG digests from each specimen, treated
with chondroitinase ABC and/or keratanases, were exam-
ined for the presence of various types of PGs using a
series of antibodies.
Intact or fragmented aggrecan in PG digests was inves-
tigated by using a polyclonal anti-aggrecan antibody. A
typical result is presented in Fig. 5A. All PG digests showed
a diversity of reactive material ranging from 60 to over 250
kDa, corresponding to almost free G1 and full-length core
protein, respectively. As expected, significant decrease in
reactivity against aggrecan was observed in LSCC in com-parison to that of healthy. Exactly the same results were
observed in the case of link protein, which was immunolo-
calised with 9/30/8A4 antibody (two major splice isoforms)
(Fig. 5B).
The presence of intact or fragmented versican in the PG
digests was investigated in a similar manner (Fig. 5C). It
was found that versican was present in all PG digests. It is
also noteworthy that LSCC contained relative higher
amounts of versican with epitopes of lower molecular size
than healthy tissue. In HNL, reactivity for versican was
observed in two bands with Mr>250 kDa, but lower-
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tioned as well as other lower-molecular size bands pre-
dominate in LSCC suggested that they represent cleavage
products of the intact versican core proteins.
Biglycan was identified in HNL but it was absent or
traces were detected in LSCC (Fig. 6A). Decorin was also
identified in varying degree of reactivity in both HNL and
LSCC (Fig. 6B). Immunoblotting of extracts from can-
cerous and healthy tissues without purification of PGs
showed that both tissues express two core proteins of
decorin, the lower band corresponding to non-glycanated
form of this PG.
PGs from normal and cancerous specimens were
assessed for the presence of GAG stubs or KS by using
monoclonal antibodies. Analyses with 3B3 monoclonal
antibody are shown in Fig. 7A. Reactivity in molecules
with a broad range of molecular size was observed in
normal specimens. In contrast, in cancerous specimens
significantly decreased levels of epitopes reactive with
3B3 antibody were observed, having high molecular size.
However, as was evident in Fig. 7B, positive immunos-
taining for lower-molecular size (less than 50 kDa) PG
metabolites was observed in both normal and cancerous
specimens using 2B6 antibody. In addition to aggrecan and
versican metabolites, the protein band of f 45 kDa had
electrophoretic mobility similar to that observed for decorin
and biglycan core proteins (see Fig. 6A and B). These PGs
seem to contain chondroitinase ABC-generated epitopes
recognized by 2B6 antibody, indicating that their GAG
chains are initiated with 4-sulfated disaccharide units.
The presence of KS on PG digests, which derived only
following chondroitinase ABC, in both normal and cancer-
ous specimens, was detected using 5D4 antibody (Fig. 7C).
In normal and cancerous specimens, the KS-bearing PGs
consisted a heterogeneous population, with profiles similar
to those obtained for aggrecan (Fig. 5A). In LSCC, a
significant decrease in KS content identical to that noticed
for aggrecan was observed.4. Discussion
Skeletal support of the larynx is provided by the hyoid
bone and cartilages, which are bridged to each other by
joints and membranes. The major cartilage of the larynx is
the cricoid, thyroid, and the paired arytenoids cartilages.
These major structural cartilages are all of hyaline type. A
major component of the abundant ECM of hyaline cartilage
is aggrecan. The epiglottis, in contrast, is composed of
elastic cartilage containing numerous fenestrations.
Substantial experimental and clinical evidences suggest
that the catabolism of ECM components is a prerequisite for
invasive and metastatic behavior of solid tumors [8]. His-
tological studies have confirmed that the cartilages and
membranes of the larynx provide natural barriers to the
spread of endolaryngeal tumors [19]. Both the thyroidcartilage and its perichondrium appear to be effective
barriers to the spread of cancer. The remodeling and
destruction of ECM of laryngeal hyaline cartilages is a
critical step to the spread and invasion of cancer. This
concept is supported by the fact that tumor invades ossified
portions of the laryngeal skeleton preferentially over carti-
laginous portions. Two common sites of early ossification
are the superior rim of the cricoid cartilage and the inferior
rim of the thyroid cartilage. Consequently, cancer cells
within the paraglottic space frequently invade these sites
as it transgresses the cricothyroid membrane [19]. However,
studies on the degeneration and destruction of the PG-rich
ECM in LSCC have not yet been published.
In order to detect changes of ECM in LSCC in vivo,
sections of HNL and LSCC were examined immunohisto-
chemically for the presence of various types of PGs with a
panel of monoclonal antibodies. As expected, strong immu-
noreactivity for aggrecan and link protein was observed in
cartilage in sections of HNL. Significant reactivity was also
observed for epitopes recognized by antibodies 3B3, 2B6
and 5D4, since 6-sulfated and 4-sulfated stubs of CS and KS
comprise basic constituents of the aggrecan molecules. In
comparison to HNL, sections of LSCC revealed an exces-
sive reduction in reactivity for both aggregate components
and aggrecan constituents of cartilage. In all cases of LSCC,
a significant destruction of the cartilage was observed that
was frequently accompanied by ossification. These histo-
logical features are compatible with the advanced stage of
the lesion since they are critical for cancer spread as
discussed above. The immunohistochemical findings were
confirmed completely by Western blot analyses. The anal-
yses with anti-aggrecan revealed that the range of size of the
fragments or intact core proteins of aggrecan differed
significantly between HNL and LSCC. In addition, analyses
with antibodies 3B3, 2B6 and 5D4 showed that the distri-
bution of the epitopes on core protein of aggrecan, which
are reactive with these monoclonal antibodies, presented
similar differences to those observed for aggrecan.
In contrast, versican and decorin, which consist a minor
PG proportion in HNL, presented an increased reactivity in
tumor-associated stroma in LSCC in comparison to HNL.
The presence of versican and decorin in HNL was not
surprising, since it has been reported that these PGs are
present in the loose connective tissues of various organs
[3,20]. In our study, the presence of non-glycanated form for
decorin was detected in both HNL and LSCC. The presence
of non-glycanated forms for decorin has also been observed
in other tissues but their significance has not been docu-
mented yet [4]. Moreover, Western blot analysis for versican
indicated that core proteins of versican are markedly frag-
mented in LSCC in comparison to HNL. Versican and
decorin are abnormally expressed in a wide variety of
malignant tumors.
Versican is a member of the hyalectan family and plays
important roles in forming hyaluronan-rich matrix provid-
ing cells with an anti-adhesive environment [21–23] and
S.S. Skandalis et al. / Biochimica et Biophysica Acta 1689 (2004) 152–161160also supports cancer cell growth. Decorin is a powerful
modulator of cell growth by affecting several key ele-
ments including matrix assembly, growth factor binding,
and receptor tyrosine kinase activity [3,24–26]. Decorin
levels are suppressed in most transformed cells, but
markedly increased in the peritumorous stroma of several
types of cancer. The latter may represent a natural
biological response of the host cells to the invading
neoplastic cells [3].
Biglycan was detected by Western blot analysis in HNL
only. The negative immunoreactivity in LSCC does not
signify the completely absence of biglycan in LSCC.
Quantification of the observed qualitative changes by
detailed biochemical analyses indicated that the concentra-
tion of KS/CS/DS-PGs in LSCC decreased dramatically
about 18-fold in comparison to HNL. Clearly, this decrease
is due to aggrecan loss, since the other two PGs, versican
and decorin, appear to increase. These dramatic changes
imply that ECM of the laryngeal cartilages in LSCC under-
goes significant degeneration, which is due to the decrease
of aggrecan and link protein. The decrease of aggrecan in
LSCC is thought to be mainly a consequence of increased
degradation of this PG in the peritumorous cartilage, al-
though the possibility for down-regulation of aggrecan
biosynthesis in this tissue should not be excluded.
LSCC is characterized by altered sulfation pattern. An
increase in the proportion of Ddi-4S in total extracted PGs
was observed in LSCC in comparison to those from healthy
samples. This finding is in accordance with other observa-
tions [9,27], and the results suggest tissue-specific biosyn-
thetic responses in various types of cancers [28], since in
rectum [29], colon [30], pancreatic [31] and gastric [17]
adenocarcinomas, the proportion of Ddi-4S was found to be
significantly decreased, as compared with that of the healthy
tissue.
In conclusion, the increased catabolism of the cartilage
PG aggrecan is a principal pathological process, which leads
to the degeneration of laryngeal cartilage in LSCC. The
consequent loss of CS and KS, which are intrinsic compo-
nents of the aggrecan molecule, disturbs both the functional
roles and structural integrity of the cartilage matrix. Over
time, this process leads to irreversible cartilage erosion with
the consequential result of the laryngeal cartilage losing its
ability to behave as natural barrier to the spread and
invasion of cancer. In situ degradation of aggrecan is a
proteolytic process involving cleavage at specific peptide
bonds located within the core protein. The mechanism of
aggrecan degradation in LSCC comes as a provocative
question that needs urgent answer.Acknowledgements
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